Organizing committee UKF - uniklinik-freiburg.de · Medical School and director of the Mul-tiple...
2
Stand bei Drucklegung August 2017 Herausgeber: © Universitätsklinikum Freiburg Redaktion: Klinik für Innere Medizin I Gestaltung: Medienzentrum | Universitätsklinikum Freiburg MULTIPLE MYELOMA 2017 KEEPING TRACK IN A MULTIFACETED LANDSCAPE OF TREATMENT STRATEGIES 8 th Freiburg Myeloma Workshop 2017 SCIENTIFIC MEETING Wednesday | October 25th 6.00 - 9.00 pm Großer Hörsaal, Medical Department DR. NOOPUR RAJE MASS GENERAL HOSPITAL | BOSTON | USA Dr. Raje is associate professor at Harvard Medical School and director of the Mul- tiple Myeloma Center at Massachusetts General Hospital, Boston, USA. She heads a translational research program evaluat- ing novel therapeutics in myeloma with a special interest in the biology of myeloma bone disease. Dr. Raje is also recipient of numerous awards including the Multiple Myeloma Senior Research Award. DR. FRANCESCA GAY UNIVERSITY OF TORINO | ITALY As a leading member of the GIMEMA (Gruppo Italiano Malattie EMatologiche dell‘Adulto), Dr. Gay has been principal investigator to various phase II/III trials on relapsed myeloma, many of them highly published in peer-reviewed journals. Dr. Gay is practising hematology at the Uni- versity of Torino, Italy and is specifically interested in tansplant-related topics. DR. HOLGER AUNER IMPERIAL COLLEGE LONDON | UK Dr. Auner is a Senior Clinical Lecturer and Consultant at the Imperial College London Centre for Haematology. He received his MD from Karl-Franzens University Graz, Austria, where he also trained in Inter- nal Medicine. He is eagerly engaged in EBMT activities. He is a clinical expert on multiple myeloma and amyloidosis. His scientific interest focuses, amongst others, on the role of autologous stem cell transplantation for myeloma. Organizing committee UKF Universitätsklinikum Freiburg Klinik für Innere Medizin I Hämatologie, Onkologie und Stammzelltransplantation Hugstetter Straße 55 | 79106 Freiburg Prof. Dr. Monika Engelhardt Dr. Johannes Waldschmidt Prof. Dr. Ralph Wäsch Silke Wenske Monika Falahen and Universitätsklinikum Freiburg Unternehmenskommunikation Elke Bührer Telefon 0761 270-19210 [email protected] Internet: www.uniklinik-freiburg.de/medizin1 www.uniklinik-freiburg.de/cccf Certification This meeting qualifies for certification from the Landesärztekammer Baden Württemberg. Sponsors We thank all our sponsors for greatly supporting this meeting. Platinumsponsors 10000 € Amgen GmbH Celgene GmbH Goldsponsors 5000 € Janssen-Cilag GmbH Silversponsors 2000 € Bristol-Myers Squibb GmbH & Co. KG Takeda Pharma Vertrieb GmbH & Co. KG Bronzesponsors 1000 € AbbVie Deutschland GmbH & Co. KG Mundipharma Deutschland GmbH & Co. KG
Transcript of Organizing committee UKF - uniklinik-freiburg.de · Medical School and director of the Mul-tiple...
Stand bei Drucklegung August 2017Herausgeber: © Universitätsklinikum Freiburg Redaktion: Klinik für Innere Medizin IGestaltung: Medienzentrum | Universitätsklinikum Freiburg
MULTIPLE MYELOMA 2017KEEPING TRACK IN A MULTIFACETED LANDSCAPE OF TREATMENT STRATEGIES
8th Freiburg Myeloma Workshop 2017
SCIENTIFIC MEETINGWednesday | October 25th 6.00 - 9.00 pmGroßer Hörsaal, Medical Department
DR. NOOPUR RAJE MASS GENERAL HOSPITAL | BOSTON | USADr. Raje is associate professor at Harvard Medical School and director of the Mul-tiple Myeloma Center at Massachusetts General Hospital, Boston, USA. She heads a translational research program evaluat-ing novel therapeutics in myeloma with a special interest in the biology of myeloma bone disease. Dr. Raje is also recipient of numerous awards including the Multiple Myeloma Senior Research Award.
DR. FRANCESCA GAYUNIVERSITY OF TORINO | ITALYAs a leading member of the GIMEMA (Gruppo Italiano Malattie EMatologiche dell‘Adulto), Dr. Gay has been principal investigator to various phase II/III trials on relapsed myeloma, many of them highly published in peer-reviewed journals. Dr. Gay is practising hematology at the Uni-versity of Torino, Italy and is specifically interested in tansplant-related topics.
DR. HOLGER AUNERIMPERIAL COLLEGE LONDON | UKDr. Auner is a Senior Clinical Lecturer and Consultant at the Imperial College London Centre for Haematology. He received his MD from Karl-Franzens University Graz, Austria, where he also trained in Inter-nal Medicine. He is eagerly engaged in EBMT activities. He is a clinical expert on multiple myeloma and amyloidosis. His scientific interest focuses, amongst others, on the role of autologous stem cell transplantation for myeloma.
Organizing committee UKFUniversitätsklinikum Freiburg Klinik für Innere Medizin IHämatologie, Onkologie und StammzelltransplantationHugstetter Straße 55 | 79106 Freiburg
Prof. Dr. Monika EngelhardtDr. Johannes WaldschmidtProf. Dr. Ralph WäschSilke WenskeMonika Falahen
and Universitätsklinikum FreiburgUnternehmenskommunikationElke BührerTelefon 0761 [email protected]
Internet:
www.uniklinik-freiburg.de/medizin1www.uniklinik-freiburg.de/cccf
CertificationThis meeting qualifies for certification from the Landesärztekammer Baden Württemberg.
SponsorsWe thank all our sponsors for greatly supporting this meeting.
Platinumsponsors 10000 €Amgen GmbHCelgene GmbH
Goldsponsors 5000 €Janssen-Cilag GmbH
Silversponsors 2000 €Bristol-Myers Squibb GmbH & Co. KGTakeda Pharma Vertrieb GmbH & Co. KG
Bronzesponsors 1000 €AbbVie Deutschland GmbH & Co. KGMundipharma Deutschland GmbH & Co. KG
Session I: Interdisciplinarity in myeloma treatmentChair: Ralph Wäsch
18.00- 18.10 (5‘)
Welcome and IntroductionJustus Duyster
18.10 - 18.25(2x5+5‘‘)
Joint Case reportGeorg HergetHenning SchäferComment: Henning Pelz
18.25 - 18.45(15‘+5‘)
Relapsed Myeloma- the Italian perspectiveFrancesca GayComment: Monika Engelhardt
18.45 - 19.00 (10‘+5‘)
Risk prediction models, including current projectsSophia Scheubeck Sandra Dold Laura Gengenbach Martin KöhlerComment: Richard Fischer
19.00 - 19.20 (15‘+5‘)
Autotransplant- still up to date in the era of novel agents?Holger AunerComment: Johannes Waldschmidt
Session II: Novel therapy insightsChair: Johannes Waldschmidt
19.20 - 19.45 (20‘+5‘)
Expert perspective on translating preclinical data to daily routineNoopur RajeComment: Stefan Müller
19.45 - 20.00 (10‘+5‘)
Novel insights and treatment strategiesRalph WäschComment: Matthias Zaiss
20.00 - 20.10(2x5‘)
What to adopt for the daily routine? Comments I + II + closing remarksMatthias EggerPaul Graf la Rosée
20.10.-21.00
Session end and get-together: snacks & drinks
Welcoming note Program
Dear colleagues,following the annual tradition of assembling peer experts at Freiburg University and let them share their insights on advances in multiple myeloma, we are happy to welcome you all to the 8th Freiburg Myeloma Workshop 2017. Over the last years, substantial advances in the field have steadily improved the outcome of patients suffering from plasma cell dyscrasias. Today´s myeloma doctors, both in the clinics and outpatient offices, face difficulties as the options available add up to a whole variety of valuable treatment strategies, including therapies as diverse as autologous and allogeneic stem cell transplantion, antibodies, checkpoint inhibitors and phase I novel agents.
„Multiple Myeloma 2017 - keeping track in a multifaceted landscape of treatment strategies“ is the title of our 2017 meeting. Expert speakers from Boston, London and Turin will share their perspectives on how to conduct individualized and risk-adapted state-of-the-art multiple myeloma treatment. These major talks will be accompanied by additional insights and comments of orthopedists, radiotherapists and hematolo-gists who will illustrate, how interdisciplinary myeloma care is cutting its path to Freiburg and the Black Forest region.
An additional meet-the-professor session will be held on Wednesday, October 25th, 3-5 pm. This session is open to all colleagues, young scientists and students and provides direct interaction with our outstanding external speakers. A “get-together” reception on Wednesday night will contribute to a hopefully inspiring and enjoyable meeting in Germany´s „eco-capital“.
Cordially looking forward to seeing you in October,
Prof. Dr. Justus Duyster Ärztlicher Direktor
Klinik für Innere Medizin ISchwerpunkt Hämatologie, Onkologie und Stammzelltransplantation und
Klinischer DirektorTumorzentrum Freiburg - CCCFUniversitätsklinikum Freiburg
Prof. Dr. Monika EngelhardtSektionsleitung Klinische Forschung & ECTU + MM-Programm
Klinik für Innere Medizin ISchwerpunkt Hämatologie, Onkologie und StammzelltransplantationUniversitätsklinikum Freiburg
Dr. Holger Auner Centre for Haematology, Imperial College London
Prof. Dr. Justus Duyster Klinik für Innere Medizin I, Hämatologie, Onkologie & Stammzell- transplantation, Universitätsklinikum Freiburg
M.Sc. Molecular Medicine Sandra Dold Klinik für Innere Medizin I, Universitätsklinikum Freiburg
Dr. Matthias Egger MVZ Klinikum Lahr
Prof. Dr. Monika Engelhardt Klinik für Innere Medizin I, Universitätsklinikum Freiburg
Prof. Dr. Richard Fischer Onkologie 3-Ländereck, Lörrach
Dr. Francesca Gay Department of Hematology, University Hospital Torino, Italy
cand. med. Laura Gengenbach Klinik für Innere Medizin I, Universitätsklinikum Freiburg
Prof. Dr. Paul Graf la Rosée Klinik für Innere Medizin II, Schwarzwald-Baar Klinikum Villingen-Schwenningen
Prof. Dr. Georg Herget Klinik für Orthopädie und Unfallchirurgie, Universitätsklinikum Freiburg
Dr. Martin Köhler Klinik für Innere Medizin I, Universitätsklinikum Freiburg
Dipl. Pharm. Stefan Müller Klinik für Innere Medizin I, Universitätsklinikum Freiburg
Dr. Henning Pelz Onkologisches Zentrum Offenburg
Prof. Dr. Noopur Raje Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, USA
Dr. Henning Schäfer Klinik für Strahlenheilkunde, Universitätsklinikum Freiburg
cand.med. Sophia Scheubeck Klinik für Innere Medizin I, Universitätsklinikum Freiburg
Dr. Johannes Waldschmidt Klinik für Innere Medizin I, Universitätsklinikum Freiburg
Prof. Dr. Ralph Wäsch Klinik für Innere Medizin I, Universitätsklinikum Freiburg
Dr. Matthias Zaiss Praxis für Interdisziplinäre Onkologie & Hämatologie, Freiburg
Speakers and chairs:
